GlassScriptPhysician profile
Lakeyn L Smith
NPI 1467115600
$1,676.17
in general payments reported to CMS, 2019-2025
30 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.20 · 2023: $759 · 2024: $409 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $310.92 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $179.84 | 2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $172.96 | 2022-2025 | |
| Insulet Corporation | $110.96 | 2023-2025 | Omnipod |
| Axsome Therapeutics, INC. | $103.56 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $101.69 | 2024 | Spravato |
| Fresenius Kabi USA, LLC | $66.95 | 2023 | Idacio |
| Exact Sciences Corporation | $66.32 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $57.54 | 2023 | |
| Xeris Pharmaceuticals, INC. | $52.63 | 2023 | Recorlev |
| Janssen Biotech, INC. | $47.65 | 2023 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.35 | 2023-2024 | Ofev |
| Lilly USA, LLC | $32.75 | 2023-2025 | Jardiance |
| Organon LLC | $30.58 | 2022 | |
| Alkermes, INC. | $29.60 | 2025 | Vivitrol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $26.73 | 2023 | Tymlos |
| Braeburn INC. | $25.79 | 2024 | Brixadi |
| Amryt Pharma Holdings LTD | $25.24 | 2023 | Mycapssa |
| Ani Pharmaceuticals, INC. | $24.43 | 2023 | Purified Cortrophin Gel |
| Acella Pharmaceuticals, LLC | $18.25 | 2023 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2025 | |
| Ascendis Pharma Endocrinology INC | $17.39 | 2023 | |
| Aurinia Pharma U.S., INC. | $15.98 | 2023 | Lupkynis |
| Astellas Pharma US INC | $15.96 | 2024 | Veozah |
| Corcept Therapeutics | $15.21 | 2023 | Korlym |
| Merck Sharp & Dohme LLC | $15.10 | 2023 | Steglujan, Steglatro |
| Amgen INC. | $13.78 | 2024 | Otezla, Repatha |
| Averitas Pharma INC. | $13.48 | 2024 | Qutenza |
| Kiniksa Pharmaceuticals, LTD. | $12.93 | 2023 | Arcalyst |
| Medtronic, INC. | $12.86 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakeyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.